Recruiting Multiple Myeloma Studies in Richmond
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the contr...
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preven...
About Multiple Myeloma Clinical Trials in Richmond
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 2 multiple myeloma clinical trials recruiting participants in Richmond, VIRGINIA. These studies are seeking a combined 388 participants. Research is being sponsored by Sanofi, Janssen Research & Development, LLC. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Richmond — FAQ
Are there multiple myeloma clinical trials in Richmond?
Yes, there are 2 multiple myeloma clinical trials currently recruiting in Richmond, VIRGINIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Richmond?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Richmond research site will contact you about next steps.
Are clinical trials in Richmond free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Richmond studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 2 active trials in Richmond are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov